Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death


Geneva, Switzerland, 19 February 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that systemic treatment with its proprietary mGlu2 receptor negative allosteric modulator (NAM), ADX92639, protects vulnerable neurons against global ischemia in rats.

The neuroprotective effect of ADX92639 was studied in the 4-vessel occlusion (4VO) model of transient global ischemia in adult male rats. 4VO causes extensive degeneration of hippocampal CA1 pyramidal neurons, whereas neurons of the CA3 region are relatively spared. ADX92639 protected the CA1 neurons from ischemic neuronal death after oral administration of 30 mg/kg. The study builds on the evidence that induction of ischemia causes changes in the expression of mGlu2 receptors in the vulnerable CA1 region of the hippocampus. The data presented at the 2014 American Neuroscience Meeting, Washington D.C., was generated in collaboration with Marta Motolese, Federica Mastroiacovo, Milena Cannella, Giuseppe Battaglia and Ferdinando Nicoletti of IRCCS Neuromed, Italy.

"Neuromed scientists are world leading experts in mGlu receptor pharmacology and we are proud to have the opportunity to work with them” said Sonia Poli CSO at Addex. “These data together with data generated with our proprietary mGluR2 NAM’s in the beta amyloid-induced memory impairment model support our continued efforts to bring these compounds into development.”

About mGlu2 receptor NAM
The metabotropic receptor 2 (mGluR2) belongs to the class C GPCR family (group II mGluRs). This receptor shows a broad distribution throughout the cortex as well as high expression in the hippocampus and perforant path. Importantly, activation of mGluR2 leads to inhibition of glutamate release in the synapse and mGluR2 NAM is one of the most promising experimental therapeutic strategies for the treatment of cognitive impairment in Alzheimer’s disease. One of the Addex mGluR2 NAM was tested in the beta amyloid-induced memory impairment model in rodents which mimics aspects of pathophysiology and progressive memory impairment observed in Alzheimer’s disease. In this study, the Addex mGluR2 NAM dose-dependently reversed working memory impairment in the novel object recognition test (NOR) without affecting locomotor activity in the animals. Donepezil, a marketed drug currently used to treat symptoms of Alzheimer’s disease, was used as the positive control and the magnitude of the effect induced by the mGluR2 NAM was similar to that of donepezil in this experiment. Preclinical research from other groups suggest not only that mGluR2 NAM might slow the progression of Alzheimer’s*, an effect not seen with any marketed drug, but also that it may have a synergistic effect on cognition** when combined with donepezil. Alzheimer’s disease represents a large and growing market with unmet medical need. None of the currently marketed drugs for Alzheimer’s disease offers patients sustained life-changing benefits. Addex is currently optimizing multiple chemical series of mGluR2 NAMs offering advanced compounds at the late stage of lead optimization. Although other drugs targeting mGluR2 are in development none are known to be as exquisitely selective for mGluR2 over other mGlu receptors (1-8) as the Addex compounds. As a result, Addex is developing the most advanced subtype selective mGluR2 NAM, a differentiating factor that may confer significant advantages in terms of efficacy and safety in later testing.

* The Journal of Neuroscience, March 17, 2010; 30(11):3870-3875
** Bioorganic & Medicinal Chemistry Letters, Dec 1, 2010; 20(23):6969-6974

About the Istituto Neurologico Mediterraneo Neuromed
Neuromed is a Scientific Institute for Hospitalization, Treatment and Research (IRCCS), a Center for Neuroscience with high specialization in Neurology, Neurosurgery, Neuro-recovery, Neuroradiology and Neurovascular Diseases.

About Addex Therapeutics
Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) has successfully completed a Phase 2A POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase 2B for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia and treatment resistant depression is being investigated. Addex second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase 1 and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGlu4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGlu2NAM for treatment resistant depression and cognitive deficits; mGlu7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Tim Dyer
Chief Executive Officer
Addex Therapeutics
Telephone: +41 22 884 15 61
Email: PR(at) 

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.